This interaction is, also, supported by an independent study, which suggested that this miRNA exerts its role in B-CLL via downregulation of TP53 and uncovered the therapeutic potential of miR-BHRF1-1 [119]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.